Tim-3 Expression Defines Regulatory T Cells in Human Tumors

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yan, Jing ^a   Zhang, Yi ^b   Zhang, Jing Ping ^a   Liang, Jing ^b   Li, Lian ^b   Zheng, Limin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ECALECTIN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MEMBRANE PROTEIN; TIM 3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; FEMALE; GALECTINS; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-2; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84874635440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058006     Document Type: Article

References (56)

1. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541.
2. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, et al. (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4: 1093-1101.
3. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, et al. (2003) Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4: 1102-1110.
4. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245-1252.
5. Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, et al. (2007) TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 127: 906-914.
6. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, et al. (2012) Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119: 3064-3072.
7. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK, (2011) Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 32: 345-349.
8. Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK, et al. (2006) Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med 203: 1413-1418.
9. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763-2779.
10. Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, et al. (2009) Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol 6: 35-43.
11. Wu W, Shi Y, Li S, Zhang Y, Liu Y, et al. (2012) Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol. 42: 1180-1191.
12. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, et al. (2009) Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 83: 9122-9130.
13. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, et al. (2010) Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 6: e1000882.
14. Gupta S, Thornley TB, Gao W, Larocca R, Turka LA, et al. (2012) Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest 122: 2395-2404.
15. Moorman JP, Wang JM, Zhang Y, Ji XJ, Ma CJ, et al. (2012) Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J Immunol 189: 755-766.
16. Li H, Wu K, Tao K, Chen L, Zheng Q, et al. (2012) Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56: 1342-1351.
17. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187-2194.
18. Gao X, Zhu Y, Li G, Huang H, Zhang G, et al. (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 7: e30676.
19. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207: 2175-2186.
20. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, et al. (2012) IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122: 1271-1282.
21. Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, et al. (2010) Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol 185: 1383-1392.
22. Simmons WJ, Koneru M, Mohindru M, Thomas R, Cutro S, et al. (2005) Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms. J Immunol 174: 1405-1415.
23. Geng H, Zhang GM, Li D, Zhang H, Yuan Y, et al. (2006) Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol 176: 1411-1420.
24. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, et al. (2008) Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181: 7660-7669.
25. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, et al. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989.
26. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, et al. (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206: 1327-1337.
27. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, et al. (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51: 154-164.
28. Zhou J, Ding T, Pan W, Zhu LY, Li L, et al. (2009) Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 125: 1640-1648.
29. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328-2339.
30. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
31. Chen M, Guo Z, Ju W, Ryffel B, He X, et al. (2012) The development and function of follicular helper T cells in immune responses. Cell Mol Immunol 9: 375-379.
32. Biswas SK, Mantovani A, (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
33. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, et al. (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
34. Blank C, Mackensen A, (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56: 739-745.
35. Keir ME, Butte MJ, Freeman GJ, Sharpe AH, (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704.
36. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, et al. (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203: 1693-1700.
37. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
38. Sakaguchi S, Miyara M, Costantino CM, Hafler DA, (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490-500.
39. Zheng Y, Rudensky AY, (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457-462.
40. Li L, Godfrey WR, Porter SB, Ge Y, June CH, et al. (2005) CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106: 3068-3073.
41. Wiersma VR, de Bruyn M, Helfrich W, Bremer E (2011) Therapeutic potential of Galectin-9 in human disease. Med Res Rev.
42. Hu G, Liu Z, Zheng C, Zheng SG, (2010) Antigen-non-specific regulation centered on CD25+Foxp3+ Treg cells. Cell Mol Immunol 7: 414-418.
43. Abastado JP, (2012) The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res 72: 2159-2161.
44. Piersma SJ, Welters MJ, van der Burg SH, (2008) Tumor-specific regulatory T cells in cancer patients. Hum Immunol 69: 241-249.
45. He J, Tang XF, Chen QY, Mai HQ, Huang ZF, et al. (2012) Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chin J Cancer 31: 287-294.
46. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, et al. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168: 4272-4276.
47. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69: 2000-2009.
48. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW, (2006) Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 176: 2808-2816.
49. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, et al. (2010) A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 5: e9504.
50. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, et al. (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127: 78-88.
51. Ngiow SF, Teng MW, Smyth MJ, (2011) Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res 71: 6567-6571.
52. Anderson AC, (2012) Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 24: 213-216.
53. Fridman WH, Pages F, Sautes-Fridman C, Galon J, (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306.
54. Bjorkstrom NK, Ljunggren HG, Sandberg JK, (2010) CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol 31: 401-406.
55. Gao Q, Wang XY, Qiu SJ, Zhou J, Shi YH, et al. (2011) Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer Sci 102: 1522-1531.
56. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, et al. (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72: 887-896.